1

2
Connelly Robert I, Powell Kenneth G, Shermer Charles D: Wearable, self-contained drug infusion device. Becton Dickinson Co, February 6, 2002: EP1177802-A1 (252 worldwide citation)

A wearable, self-contained drug infusion device is disclosed that is capable of achieving the precise flow rate control needed for dose-critical drugs such as insulin. In preferred embodiments of the device, piezoelectrically-actuated valve or pump structures are used in combination with thermal flo ...


3
Bylund Adam David, Durban William Jefferey, Wardle Michael D, Long Karen M, Mcclusky Joseph, Kraft Ulrich, Ebner Manfred, Steine Matthias: Systems for remotely controlling medication infusion and analyte monitoring. Lifescan, August 27, 2003: EP1338295-A1 (247 worldwide citation)

Devices, systems and methods are provided for remotely controlling medication delivery to a patient by means of a medication infusion pump, such as a subcutaneous infusion pump, and for remotely controlling the monitoring of one or more physiological fluid analytes such as by a percutaneous measurem ...


4
Feijen Jan, Esselbrugge Hilbert: Article for the controlled delivery of an active substance, comprising a hollow space fully enclosed by a wall and filled in full or in part with one or more active substances.. Akzo, November 25, 1992: EP0514406-A1 (190 worldwide citation)

An article for the controlled delivery of an active substance, comprising a hollow space fully enclosed by a wall and filled in full or in part with one or more active substances, which wall is made using a biodegradable polymeric material permeable to the active substance, wherein the wall is compo ...


5
Moreau Jacques Pierre, Kitchell Judith P: Delivery system.. Biomeasure, February 1, 1989: EP0301856-A2 (180 worldwide citation)

A delivery system for agents, such as therapeutic agents, or other substances includes a biodegradable polymer and the agent or substance. The delivery system is coated with a barrier substance that decreases the quantity of the agent release from the system, compared to the quantity of the agent re ...


6
Eury Robert P, Garguilo Darlene, Villareal Plaridel: Method of incorporating drugs into a polymer component of stents. Advanced Cardiovascular System, October 2, 1996: EP0734721-A2 (124 worldwide citation)

The drug-loaded polymeric material containing a therapeutic drug can be applied to a structure of an intravascular stent. A therapeutically effective amount of a therapeutic drug is incorporated into such a layer of polymeric material, without significantly increasing the thickness of the stent, to ...


7
Jenkins Anthony William, Leslie Stewart Thomas, Miller Ronald Brown: Oral pharmaceutical composition.. Euro Celtique, December 17, 1986: EP0205282-A2 (116 worldwide citation)

A sustained release, oral pharmaceutical composition in solid unit dosage form, for application to the mucosa of the oral or nasal cavity, comprises compressed, mucosa adhesive cellulose, coated granules, the granules comprising a drug, a higher aliphatic alcohol and a hydrated water soluble hydroxy ...


8
Yayon Avner, Nevo Zvi: Fgfr3 as a marker for mesenchymal skeletal progenitor cells. Yeda Res & Dev, Univ Ramot, April 8, 1998: EP0833620-A1 (111 worldwide citation)

The present invention concerns fibroblast growth factor 9 (FGF9) as a high affinity ligand for fibroblast growth factor receptor 3 (FGFR3) which ligand is capable of binding and activating FGFR3 in a specific manner. The present invention is also directed to methods for detection of FGFR3 by utilizi ...


9
Yamahira Yoshiya, Fujioka Keiji, Sato Shigeji, Yoshida Noboru: Prolonged sustained-release preparations.. Sumitomo Chemical Co, May 2, 1985: EP0139286-A2 (110 worldwide citation)

A sustained-release preparation in the form of a needle-like or bar-like shape, which comprises an active ingredient and a pharmaceutically acceptable biodegradable carrier (e.g. proteins, polysaccharides and synthetic high molecular compounds, preferably collagen, atelocollagen, gelatin, and a mixt ...


10
Wong Vernon G: Ocular implants.. Visionex, June 5, 1991: EP0430539-A2 (108 worldwide citation)

Ocular implants are formed so as to be insertable in the suprachoroid of the eye, preferably in the form of plaques 0.5 to 10 mm x 0.5 to 10 mm, and 0.25 to 1.0 mm thick. They are made from a pharmacologically acceptable biodegradable polymer, such as a polyester, incorporating an active agent for t ...